Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

With the aim of fuelling open‐source, translational, early‐stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non‐cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead‐generation activities. Two additional drug‐discovery‐relevant datasets are included: a) a drug‐like property analysis reflecting the latest lead‐like guidelines and b) an early lead‐generation package of the most promising hits within the clusters identified.

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  David Beer,et al.  A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis , 2012, ACS chemical biology.

[3]  Michael S. Scherman,et al.  INHIBITION OF MYCOLIC ACID TRANSPORT ACROSS THE MYCOBACTERIUM TUBERCULOSIS PLASMA MEMBRANE , 2011, Nature chemical biology.

[4]  R. Young.  The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry? , 2011, Bioorganic & medicinal chemistry letters.

[5]  Darren V S Green,et al.  Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.

[6]  Takushi Kaneko,et al.  Challenges and opportunities in developing novel drugs for TB. , 2011, Future medicinal chemistry.

[7]  P. Hipskind,et al.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. , 2011, ACS medicinal chemistry letters.

[8]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[9]  A. Hill,et al.  Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.

[10]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[11]  P. Cardona,et al.  Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.

[12]  O. Kon,et al.  Multidrug- and extensively drug-resistant tuberculosis: an emerging threat , 2009, European Respiratory Review.

[13]  R. Goldman,et al.  Discovery and validation of new antitubercular compounds as potential drug leads and probes. , 2009, Tuberculosis.

[14]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.

[15]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[16]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[17]  David Brown,et al.  Unfinished business: target-based drug discovery. , 2007, Drug discovery today.

[18]  Julian Parkhill,et al.  The complete genome sequence of Mycobacterium bovis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Darko Butina,et al.  Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets , 1999, J. Chem. Inf. Comput. Sci..

[20]  I. Orme,et al.  Animal Models of Mycobacteria Infection , 1999, Current protocols in immunology.

[21]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[22]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[23]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[24]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.

[25]  K. Read,et al.  A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. , 2011, Drug metabolism letters.

[26]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[27]  Richard P. Gabriel,et al.  Innovation Happens Elsewhere , 2005 .

[28]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[29]  Global Tuberculosis Programme.  Global tuberculosis control : WHO report , 1997 .